Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 6;100(7):e1522–e1532. doi: 10.1111/aos.15148

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 1 — Percentage of patients treated with photodynamic therapy per disease, both in the normal situation and during the verteporfin shortage. These values were calculated by dividing the number of PDT‐treated patients by the number of referred patients per clinic and averaging these percentages. The absolute number of referrals is noted below the bars. AMD = age‐related macular degeneration; CSC = central serous chorioretinopathy; PCV = polypoidal choroidal vasculopathy; PDT = photodynamic therapy. [Colour figure can be viewed at wileyonlinelibrary.com]